I’d like to hear theories on why with global vaccination demand over the last year and a half we didn’t see any revenue from the syringe business on the quarterly reports. Most other publicly traded syringe manufacturers have seen huge increases in revenue and pps. Even if we outsourced or licensed out the rights to our syringe patents for that business I would have expected a pandemic positive demand impact to the revenue stream.

I wonder if Unvc has gotten out of that business or if it’s in now under a different business entity not currently included in the Unvc ‘shell’?